An interventional study of Carevix and Tenaculum in IUD, Abnormal Uterine Bleeding and Pain, Cervical, sponsored by Indiana University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Indiana University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Metrorrhagia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Metrorrhagia · United States.
Among the 43 studies in Metrorrhagia with a site in United States, this one is the 10th largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2026, is one of 23 with no phase, and was the 39th registered.
153 studies on the registry are indexed under Metrorrhagia; 34 are open to participants now.
Browse Metrorrhagia studies →8 of the 43 studies in Metrorrhagia with a site in United States are open now. Recruiting first, the newest first:
Christiana Care Health Services · Sites in United States
Ages 18+ · Women only
Channel Medsystems · Sites in United States
Ages 25+ · Women only
Eastern Virginia Medical School · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
UConn Health · Sites in United States
Ages 18+ · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Metrorrhagia studies recruiting now, 10 (50%) set no upper age limit and 10 (50%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 115 interventional studies indexed under Metrorrhagia.
Median enrollment 60 across the 40 interventional studies, 300 across the 3 observational. Of the 31 that completed or were terminated, 17 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 43 have an industry lead sponsor. The 10 most frequent:
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
Indiana University has 3 studies filed under Metrorrhagia — fewer than ten, so there is no comparison to draw.
3 of the studies in Metrorrhagia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06653400Icahn School of Medicine at Mount SinaiCombined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy | 2026-12-31 |
| NCT07290517Indiana UniversityAssessing Pain and Effectiveness of Carevix Device for IUD Insertions | 2027-03 |
| NCT07664956Christiana Care Health ServicesCyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Metrorrhagia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate patient-reported pain, bleeding, and device efficiency along with provider satisfaction and ease of use between IUD insertions using a suction cervical stabilizer (new device, FDA approved, atraumatic) and single-tooth tenaculum (standard, traumatic). Our aims are to:
Participants (including providers) will:
The primary objective is to assess and compare patient-reported pain during IUD insertion between the Carevix device and tenaculum. The hypothesis is that patient-reported pain scores comparing Carevix™ to tenaculum will be lower. The investigators will assess pain, and predictors for pain scores including nulliparous vs multiparous, when highest pain scores are reported, and expectation of pain for the procedure.
The secondary objective will be to assess Usability (provider assessment of ease of use, number of device placement attempts to secure sufficient traction on uterus), efficacy (ability to insert IUD with Carevix™ device alone without recourse to conventional tenaculum or other instruments), provider reported bleeding (cervical bleeding and ecchymosis), overall provider satisfaction, patient-reported pain scores at device placement prior to IUD insertion procedure and after completion of IUD insertion using Visual Analog Scale (VAS), overall patient satisfaction, and overall provider satisfaction. The investigators aim to expand the pilot trial data collection to assess cultural background, ethnicity and demographics while also assessing prior contraceptive choices, reasons for discontinuation of prior choices and reasons for current selection of IUD insertion and any anticipated barriers for removal.
Inclusion Criteria (to be assessed prior to procedure):
Exclusion Criteria (to be assessed by provider at time of procedure):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive the atraumatic, suction-based, cervical stabilizer (Carevix) for their IUD insertion.
Device: Carevix
Patients will receive the standard of care device (single tooth tenaculum) for their IUD insertion.
Device: Tenaculum
Vacuum cervical stabilization device
Standard of care cervical stabilization device
Patient pain score
Participants will be asked to rate their pain prior to, during, and after the IUD insertion procedure on a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."
Time frame: During Procedure (at Cervix Grasping, at Cervix Traction, and at IUD placement)
Difference in Pain Score
Participants will be asked to rate their pain prior to, during, and after the IUD insertion procedure on a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable." Pain scores will be compared among nulliparous and multiparous participants
Time frame: Prior to procedure, during procedure (at cervix grasping, at cervix traction, at IUD placement), and 5 minutes after procedure completion
Highest Pain Score
Participants will be asked to rate their pain prior to, during, and after the IUD insertion procedure on a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable." The time at which the highest pain score was reported will be compared.
Time frame: Prior to procedure, during procedure (at cervix grasping, at cervix traction, at IUD placement), and 5 minutes after procedure completion
Expectation of Pain
Participants will be asked to rate their expectation of pain on a scale of 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."
Time frame: Within 15 minutes after IUD procedure completion
Provider device satisfaction - Time to Use Device
Providers will be asked to provide their agreement that procedure time was not extended due to the device use on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"
Time frame: Immediately after IUD procedure
Provider device satisfaction - Impact on Patient Discomfort
Providers will be asked whether the device's use impacted patient discomfort on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree."
Time frame: Immediately after IUD insertion procedure
Provider device satisfaction - Device Preference
Providers will be asked to rate their overall satisfaction with the device on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"
Time frame: Immediately after IUD insertion procedure
Provider device satisfaction - Procedure Visibility
Providers will be asked to rate visibility while using the device on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"
Time frame: Immediately after IUD insertion procedure
Provider device satisfaction - Pulling Strength
Providers will be asked to rate the device's pulling strength as adequate on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"
Time frame: Immediately after IUD insertion procedure
Provider device satisfaction (Ease of Use)
Providers using the Carevix device will be asked to rate ease of use on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree."
Time frame: Immediately after IUD procedure
Number of Device Placement Attempts
Providers are asked to report the number of attempts required for device placement
Time frame: Immediately after IUD insertion procedure
Need for Device Replacement
Providers who use the Carevix device will be asked if the procedure's successful completion required replacing the Carevix device with the cervical tenaculum
Time frame: Immediately after IUD insertion procedure
Provider Reported Bleeding
The number of providers who had to manage or stop bleeding on cervical tissues will be compared.
Time frame: Immediately after IUD insertion procedure
Time to Bleeding Cessation
The time (minutes) required for the providers to stop bleeding of cervical tissues will be compared.
Time frame: Immediately after IUD procedure completion
Patient pain score
Participants will be asked to rate their pain prior to, during, and after the IUD insertion procedure on a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."
Time frame: Prior to Procedure and 5 minutes after procedure completion
Overall Patient Satisfaction
Participants will rate their satisfaction with the procedure on a 5 point Likert scale from 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"
Time frame: Immediately after IUD procedure completion
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 41 non-industry interventional studies with no phase under Metrorrhagia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 12 months is below that.
Counting every sponsor, half of 43 studies reached it within 17 months; a quarter within 6 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.